Contineum Therapeutics, Inc. (CTNM) vs Evolus, Inc. (EOLS)

A side-by-side comparison of Contineum Therapeutics, Inc. and Evolus, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CTNM

Contineum Therapeutics, Inc.

$479M

$12.72HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

EOLS

Evolus, Inc.

$492M

$7.47HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — CTNM vs EOLS

growth of $100 · dividends reinvested · last 2y

CTNM -17.4% (-9.1%/yr)EOLS -43.7% (-24.9%/yr)CTNM compounded faster over this window

CTNM EOLS

CTNM vs EOLS: by the numbers

•EOLS is the larger company ($492M vs $479M market cap).
•Both run net losses; CTNM's is the smaller (0.00% vs -10.85% net margin).

Metrics side by side

Valuation

Metric	CTNM	EOLS
P/S ratio	N/A	1.55
P/B ratio	2.00	N/A

Profitability

Metric	CTNM	EOLS
Gross margin	0.00%	66.25%
Operating margin	0.00%	-7.33%
Net margin	0.00%	-10.85%
ROE	-24.02%	N/A
ROIC	-27.22%	-15.54%

Growth (annualized)

Metric	CTNM	EOLS
Revenue CAGR (5Y)	N/A	32.82%
Total return CAGR (5Y)	N/A	0.46%

Go deeper

Full CTNM analysis Full EOLS analysis Interactive comparison tool

Dig into the metrics

Contineum Therapeutics ROE Evolus ROE Contineum Therapeutics operating margin Evolus operating margin Contineum Therapeutics revenue growth Evolus revenue growth Contineum Therapeutics free cash flow Evolus free cash flow

Contineum Therapeutics & Evolus appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.